Cargando…

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

Detalles Bibliográficos
Autores principales:	Papanikolaou, X, Rosenthal, A, Dhodapkar, M, Epstein, J, Khan, R, van Rhee, F, Jethava, Y, Waheed, S, Zangari, M, Hoering, A, Crowley, J, Alapat, D, Davies, F, Morgan, G, Barlogie, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817101/ https://www.ncbi.nlm.nih.gov/pubmed/27015287 http://dx.doi.org/10.1038/bcj.2016.19

Ejemplares similares

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma
por: Papanikolaou, X, et al.
Publicado: (2015)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma
por: Khan, R, et al.
Publicado: (2015)

Serial exome analysis of disease progression in premalignant gammopathies
por: Zhao, Siming, et al.
Publicado: (2014)

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
por: Srkalovic, Gordan, et al.
Publicado: (2014)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
por: Heuck, C J, et al.
Publicado: (2014)

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
por: Rasche, L, et al.
Publicado: (2018)

The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling
por: Weinhold, N, et al.
Publicado: (2015)

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols
por: Singh, Zeba N, et al.
Publicado: (2015)

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
por: Durie, Brian G. M., et al.
Publicado: (2020)

P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
por: Usmani, S., et al.
Publicado: (2022)

OA01.20. Enhanced hepatoprotective activity of piperine loaded optimised chitosan microspheres
por: Sahu, Prashant, et al.
Publicado: (2012)

Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy
por: Spisek, Radek, et al.
Publicado: (2007)

Flow Cytometry as a Diagnostic Tool in Monoclonal Gammopathy of Renal Significance
por: Rath, Asish, et al.
Publicado: (2023)

EHMTI-0120. Are the IHS’ recommendations for evaluation and registration of adverse events in drug trials in migraine being followed ?
por: Tfelt-Hansen, P, et al.
Publicado: (2014)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

Detection of dominant QTLs for stigma exsertion ratio in rice derived from Oryza rufipogon accession ‘W0120’
por: Bakti, Citra, et al.
Publicado: (2019)

PA01.20. Acute and sub-acute toxicological study of rasa manikya prepared with classical-modified and adopted method
por: Sud, Sushant, et al.
Publicado: (2012)

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2019)

Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
por: Louie, S G, et al.
Publicado: (2013)

P01.20. The effect of WIN-34B on cartilage protection and regeneration by chondrogenesis from subchondral bone in vitro and in vivo
por: Huh, J, et al.
Publicado: (2012)

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
por: Marcath, Lauren A., et al.
Publicado: (2021)

P834: MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES
por: Kostopoulos, Ioannis, et al.
Publicado: (2023)

Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
por: Tomasson, Michael H., et al.
Publicado: (2018)

Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat
por: Stein, Caleb K, et al.
Publicado: (2015)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

Sumoylation is Required for the Cytoplasmic Accumulation of a Subset of mRNAs
por: Zhang, Hui, et al.
Publicado: (2014)

Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
por: Damasceno, Daniela, et al.
Publicado: (2021)

Monoclonal gammopathies
por: Tozzi, S
Publicado: (2010)

WCN23-0120 MEDIUM AND LONG TERM ANTIBODY RESPONSE TO COVID-19 VACCINATION IN PATIENTS RECEIVING HEMODIALYSIS (HD) - A CROSS SECTIONAL STUDY
por: Cheema, S., et al.
Publicado: (2023)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
por: Chen, Ciao-Sin, et al.
Publicado: (2023)

Defining T Cell Subsets in Human Tonsils Using ChipCytometry
por: Hagel, Joachim P., et al.
Publicado: (2021)

THE ROLE OF A MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE DIAGNOSIS IN HEALTHCARE UTILIZATION
por: Castaneda-Avila, Maira, et al.
Publicado: (2022)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
por: Danziger, Samuel A., et al.
Publicado: (2020)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1k7h49ptju2dkop2lmrbfvgldb